Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPS 1776 for Acute Migraine
NCT00172094Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2003
- Primary completion
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of isovaleramide in migraine (3 arms), sponsored by Takeda. Primary endpoint: Response rate at 2 hours post-dose. Started Dec 2003; status: completed.
02
Drugs
isovaleramide
03
Conditions
migraine
Beyond the preview
Go deeper on NCT00172094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00172094.